Gahl William A, Balog Joan Z, Kleta Robert
National Human Genome Research Institute and Intramural Office of Rare Diseases, National Institutes of Health, Bethesda, Maryland 20892-1851, USA.
Ann Intern Med. 2007 Aug 21;147(4):242-50. doi: 10.7326/0003-4819-147-4-200708210-00006.
The full burden of nephropathic cystinosis in adulthood and the effects of long-term oral cysteamine therapy on its nonrenal complications have not been elucidated.
To assess the severity of cystinosis in adults receiving and not receiving oral cysteamine therapy.
Case series.
National Institutes of Health Clinical Center.
100 persons (58 men and 42 women) age 18 to 45 years with nephropathic cystinosis examined between January 1985 and May 2006.
Historical data were collected on renal transplantation, administration of oral cysteamine, and time and cause of death. Patients were evaluated for height and weight; thyroid, pulmonary, and swallowing function; muscle atrophy; hypogonadism (in men); retinopathy; vascular and cerebral calcifications; diabetes mellitus; and homozygosity for the common 57-kb deletion in CTNS. Laboratory studies were also performed.
Of 100 adults with nephropathic cystinosis, 92 had received a renal allograft and 33 had died. At least half of the patients had hypothyroidism, hypergonadotropic hypogonadism (in men), pulmonary insufficiency, swallowing abnormalities, or myopathy. One third of the patients had retinopathy or vascular calcifications, and 24% had diabetes. Homozygosity for the 57-kb CTNS deletion was associated with an increased risk for death and morbidity. The 39 patients who received long-term (> or =8 years) oral cysteamine therapy were taller and heavier, had a renal allograft later in life, had lower cholesterol levels, and experienced fewer complications and deaths than patients who received cysteamine for fewer than 8 years. The frequency of diabetes mellitus, myopathy, pulmonary dysfunction, hypothyroidism, and death increased as time off cysteamine treatment increased, and it decreased as time on cysteamine therapy increased.
The study was retrospective and not randomized. The criteria used to measure adequacy of treatment were arbitrary.
Untreated nephropathic cystinosis causes extensive morbidity and death in adulthood. Long-term oral cysteamine therapy mitigates these effects.
成人期肾病型胱氨酸病的全部负担以及长期口服半胱胺疗法对其非肾脏并发症的影响尚未阐明。
评估接受和未接受口服半胱胺治疗的成人胱氨酸病的严重程度。
病例系列。
国立卫生研究院临床中心。
1985年1月至2006年5月期间接受检查的100名年龄在18至45岁的肾病型胱氨酸病患者(58名男性和42名女性)。
收集有关肾移植、口服半胱胺的使用情况以及死亡时间和原因的历史数据。对患者进行身高、体重、甲状腺、肺部和吞咽功能、肌肉萎缩、性腺功能减退(男性)、视网膜病变、血管和脑钙化、糖尿病以及CTNS中常见的57kb缺失纯合性评估。还进行了实验室研究。
100名成人肾病型胱氨酸病患者中,92人接受了同种异体肾移植,33人死亡。至少一半的患者患有甲状腺功能减退、高促性腺激素性性腺功能减退(男性)、肺功能不全、吞咽异常或肌病。三分之一的患者患有视网膜病变或血管钙化,24%的患者患有糖尿病。57kb CTNS缺失纯合性与死亡和发病风险增加相关。与接受半胱胺治疗少于8年的患者相比,39名接受长期(≥8年)口服半胱胺治疗的患者更高、更重,肾移植时间更晚,胆固醇水平更低,并发症和死亡更少。随着停止半胱胺治疗时间的增加,糖尿病、肌病、肺功能障碍、甲状腺功能减退和死亡的发生率增加,而随着半胱胺治疗时间的增加而降低。
该研究为回顾性研究,未进行随机分组。用于衡量治疗充分性的标准是任意的。
未经治疗的肾病型胱氨酸病在成年期会导致广泛的发病和死亡。长期口服半胱胺疗法可减轻这些影响。